Status:
COMPLETED
Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
All Genders
30-65 years
Phase:
PHASE1
Brief Summary
The aims of the study are to assess the safety, tolerability and pharmacokinetics of ER tablets of AZD3241 following multiple ascending doses administered to healthy male and female subjects including...
Eligibility Criteria
Inclusion
- Healthy male and female subjects 30-65 years
- Body Mass Index (BMI) between 18 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg
Exclusion
- History of any clinically significant disease or disorder
- History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
- Previous history of frequent pre-syncope or syncope
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT00914303
Start Date
June 1 2009
End Date
March 1 2010
Last Update
April 6 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Uppsala, Sweden